Rare Disease & Gene Therapy — July 13, 2026
|
Mahzi Therapeutics is letting Pitt Hopkins families buy equity in its gene therapy through a Regulation Crowdfunding round — an unconventional patient-financing model — while Apertura’s NIH gene-therapy pact and Cyllene’s €33 million raise mark a rare-disease period defined by capital and collaboration rather than pivotal data.
Today’s top developments:
|
What to Watch
- Mahzi’s patient-shareholder model — Whether the Regulation Crowdfunding “community round” can scale beyond a single program without creating conflicts between investor-families and clinical-trial objectivity, a template other rare-disease gene therapy developers will watch closely.
- Apertura’s NPC1 proof-of-concept — Preclinical validation of the TfR1 CapX capsid will indicate whether intravenous, blood-brain-barrier-crossing AAV delivery can become a repeatable platform for CNS gene therapy, with regulatory and manufacturing steps contingent on the NIH collaboration.
- Cyllene’s 2027 Phase 2b/3 — The planned pivotal study of EG110A is the key readout for whether the non-replicating HSV-1 platform delivers durable efficacy in neurogenic detrusor overactivity and supports expansion into pain and migraine.
- BioMarin’s PKU franchise — How long patient-loyalty campaigns and adherence infrastructure can sustain PKU market share if a one-time gene therapy reaches late-stage clinical validation and payer acceptance within the next five years.
This brief highlights the edition’s top stories. Read the full July 13, 2026 edition → for all stories and analysis — or browse the Rare Disease & Gene Therapy archive.